A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs TAK 935 (Primary)
- Indications Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
- 03 Dec 2017 According to an Ovid Theraprutics media release, data from this trial was presented at the American Epilepsy Society (AES) 71st Annual Meeting.
- 21 Nov 2017 According to an Ovid Therapeutics media release, data from this trial will be presented at the American Epilepsy Society (AES) 71st Annual Meeting 2017.